ImageneBio, Inc. (IMA): EBITDA
-$48.05M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$48.05M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$35.90M | n/a | 2026-03-10, From 2024-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.05M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$158.43M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$24.43M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.60M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$132.54M | n/m |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | -$6.12M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$66.94M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$76.96M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$41.55M | n/m |
Compare IMA, PROK, PLUR, CRDF side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗